|21st October 2020||Bernard J Kelley||2,500||Open or private sale||$14.00||$35,006.75|
|13th October 2020||Alison Moore||11,031||Exercise of derivative||$2.27||$25,040.37|
|13th October 2020||Alison Moore||11,031||Open or private sale||$42.00||$463,302.00|
|12th October 2020||Alison Moore||24,233||Open or private sale||$42.00||$1,017,786.00|
|12th October 2020||Alison Moore||24,233||Exercise of derivative||$2.27||$55,008.91|
|9th October 2020||Byron L Dorgan||25,000||Exercise of derivative||$10.63||$265,750.00|
|9th October 2020||Alison Moore||30,199||Exercise of derivative||$2.27||$68,551.73|
|9th October 2020||Alison Moore||39,509||Open or private sale||$41.00||$1,619,869.00|
|9th October 2020||Byron L Dorgan||25,000||Open or private sale||$13.54||$338,527.50|
|8th October 2020||Byron L Dorgan||25,000||Exercise of derivative||$10.63||$265,750.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels.